Search Medical Condition
Please enter condition
Please choose location from dropdown
 

Cypress, California Clinical Trials

A listing of Cypress, California clinical trials actively recruiting patient volunteers.

RESULTS

Found (950) clinical trials

A Safety Tolerability Pharmacokinetics and Immunogenicity Trial of Co-administered MERS-CoV Antibodies REGN3048 and REGN3051

This is a Phase 1, first-in-human (FIH), single site, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, PK, and immunogenicity of single ascending doses of a co-administered (1:1, w/w) combination of REGN3048 and REGN3051 mAb's, administered IV in healthy adult volunteers. Study duration of approximately 16 months. Approximately 48 ...

Phase

0.05 miles

Learn More »

A Comparison of Subject-administered Romosozumab With Healthcare Provider-administered Romosozumab for Osteoporosis

To evaluate the noninferiority of a 6-month treatment with 210 mg romosozumab at 90 mg/mL administered subcutaneously (SC) once a month (QM) in postmenopausal women with osteoporosis either by healthcare provider (HCP) administration with prefilled syringe (PFS) or by subject self-administration with autoinjector/pen (AI/Pen)

Phase

0.05 miles

Learn More »

A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Moderate to Severe Crohn's Disease

The purpose of this study is to evaluate the potential effects of an intravenous (IV) induction and subcutaneous (SC) maintenance administration of ustekinumab on the pharmacokinetic (PK) of a cocktail of representative probe substrates of cytochrome P450 (CYP) enzymes (CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2) in participants with moderate to ...

Phase

0.05 miles

Learn More »

PK and PD Profile of Dance 501 in Healthy Non-diabetic Subjects With Mild to Moderate Asthma or COPD

The PK and PD profile of Dance 501 (Human Insulin Inhalation Solution and Inhaler) will be compared to subcutaneous injection of insulin lispro.

Phase

0.05 miles

Learn More »

A Study to Assess the Effects of Age and Gender on the Pharmacokinetics of JNJ-42847922 in Healthy Adults

The purpose of this study is to assess the pharmacokinetics of single-dose evening administration of JNJ-42847922 in elderly non-Asian adults compared with weight- and gender-matched young healthy non-Asian adults and to assess the pharmacokinetics of single-dose evening administration of JNJ-42847922 in healthy Japanese adults.

Phase

0.1 miles

Learn More »

Safety Tolerability Pharmacokinetics and Efficacy of LMB763 in Patients With NASH

The purpose of the present study is to assess the effects of LMB763 with respect to safety, tolerability, and on markers of liver inflammation in patients with NASH

Phase

0.1 miles

Learn More »

Dose Range Finding Study of Bimagrumab in Sarcopenia

The purpose of this study is to determine the efficacy of repeat dosing with multiple dose levels of bimagrumab on patient physical function, skeletal muscle mass and strength in older adults with sarcopenia. In addition, this study will generate data on the safety, tolerability, and pharmacokinetics of bimagrumab in older ...

Phase

0.1 miles

Learn More »

Compare Bioavailability of BMS-986089 After Subcutaneous Injection

Randomized study in healthy men and women. Assess the similarity of BMS-986089 when injected into the arm, thigh, or the stomach. Collect data on safety of BMS-986089.

Phase

0.1 miles

Learn More »

A Multiple Dose Study to Evaluate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of BMS-986263 in Healthy Participants

The purpose of this study is to assess the safety and tolerability of BMS-986263 in healthy volunteers.

Phase

0.1 miles

Learn More »

Study Comparing TPI-120 and Neulasta Administered Through Subcutaneous Route in Healthy Adult Subjects

The current study design was prepared to assess and compare the PK, PD, safety, tolerability of the Adello biosimilar candidate, TPI-120 and the US-licensed reference product, Neulasta after administering a single subcutaneous 2 mg dose in healthy adult subjects in a crossover design. The primary PK parameters are AUC0-t, AUC0-inf, ...

Phase

0.1 miles

Learn More »